Cargando…
Is there an effect of intranasal insulin on development and behaviour in Phelan-McDermid syndrome? A randomized, double-blind, placebo-controlled trial
Phelan-McDermid syndrome (PMS) or 22q13.3 deletion syndrome is a rare neurodevelopmental disorder with at least 60 children and 35 adults diagnosed in the Netherlands. Clinical features are moderate to severe intellectual disability and behavioural problems in the autism spectrum. Other researchers...
Autores principales: | Zwanenburg, Renée J, Bocca, Gianni, Ruiter, Selma A J, Dillingh, Jan H, Flapper, Boudien C T, van den Heuvel, Edwin R, van Ravenswaaij-Arts, Conny M A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117914/ https://www.ncbi.nlm.nih.gov/pubmed/27577546 http://dx.doi.org/10.1038/ejhg.2016.109 |
Ejemplares similares
-
Understanding Behavior in Phelan-McDermid Syndrome
por: Landlust, Annemiek M., et al.
Publicado: (2022) -
Developmental phenotype in Phelan-McDermid (22q13.3 deletion) syndrome: a systematic and prospective study in 34 children
por: Zwanenburg, Renée J., et al.
Publicado: (2016) -
Phelan-McDermid syndrome: a classification system after 30 years of experience
por: Phelan, Katy, et al.
Publicado: (2022) -
A randomized controlled trial of intranasal oxytocin in Phelan-McDermid syndrome
por: Fastman, J., et al.
Publicado: (2021) -
Characterisation of the clinical phenotype in Phelan-McDermid syndrome
por: Burdeus-Olavarrieta, Mónica, et al.
Publicado: (2021)